{"id":"W4324136966","doi":"10.1200/jco.2023.41.6_suppl.lba440","title":"Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Atezolizumab; Internal medicine; Clinical endpoint; Placebo; Gemcitabine; Metastatic Urothelial Carcinoma; Urology; Oncology; Gastroenterology; Randomized controlled trial; Chemotherapy; Cancer; Pembrolizumab; Urothelial carcinoma; Bladder cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002152206,0.0009787327,0.001609913,0.0004046744,0.0002017118,0.0007398243,0.0006911544,0.001061982,0.003984695],"category_scores_gemma":[0.001278186,0.0003470145,0.001597689,0.0003451885,0.0005499505,0.0006304597,0.0004153518,0.00219941,0.0005460261],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006254337,"about_ca_system_score_gemma":0.0008169207,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005644761,"about_ca_topic_score_gemma":0.0017617,"domain_scores_codex":[0.9994901,0.0003157367,0.00002975904,0.00006044778,0.00003460944,0.00006934789],"domain_scores_gemma":[0.99923,0.0002479454,0.0002170438,0.00005477981,0.00002363301,0.0002266653],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9547702,0.005201161,0.001119103,0.0005541994,0.0007397195,0.00002803145,0.00003899654,0.0006640146,0.004409992,0.00008688034,0.0009025552,0.03148521],"study_design_scores_gemma":[0.6804315,0.3042602,0.008964759,0.00009526414,0.001530494,0.00009282318,0.00002726517,0.0009086818,0.00194337,0.0003085431,0.001414052,0.0000230031],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888068,0.004098171,0.0006334029,0.0005341364,0.0001912139,0.001807971,0.001766366,0.000115483,0.002046444],"genre_scores_gemma":[0.9903399,0.001968798,0.001245727,0.0008052261,0.0001851128,0.001762735,0.00165922,0.00002732287,0.002005905],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003984695,"threshold_uncertainty_score":0.0133301,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2011807970561828,"score_gpt":0.4844403628881609,"score_spread":0.2832595658319782,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}